Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.64 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376270 | 0.84 | MAPK14 (0.68) | MAPK14 | |
| SCHEMBL6829444 | 0.83 | MAPK14 (0.63) | MAPK14ALDH1A1FOLH1 | |
| SCHEMBL4480128 | 0.81 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL4470415 | 0.79 | MAPK14 (1.00) | MAPK14ALDH1A1 | |
| SCHEMBL4488411 | 0.79 | MAPK14 (0.74) | MAPK14ALDH1A1 | |
| SCHEMBL4384662 | 0.79 | MAPK14 (0.74) | MAPK14ALDH1A1 | |
| SCHEMBL4475064 | 0.78 | MAPK14 (0.81) | MAPK14PTGER1ALDH1A1 | |
| SCHEMBL4376128 | 0.78 | MAPK14 (0.85) | MAPK14ALDH1A1 | |
| SCHEMBL4389618 | 0.78 | MAPK14 (0.85) | MAPK14ALDH1A1 | |
| SCHEMBL4379388 | 0.77 | MAPK14 (0.60) | MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | MAPK14 53/4885PTGER1 102/4885MRGPRX4 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.